ESMO 2026 | CCTG PR21: patient-reported QoL with docetaxel vs lutetium-PSMA in mCRPC

Name: CCTG PR21: patient-reported QoL with docetaxel vs lutetium-PSMA in mCRPC
Uploaded: 2026-10-23T00:00:00Z
Duration: 3 min 22 s

Daniel Khalaf • 23 Oct 2026

ESMO 2026

Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617 Docetaxel

CCTG PR21

Daniel Khalaf, MD, University of Toronto, Toronto, Canada, explores patient-reported quality of life (QoL) outcomes from the Canadian Cancer Trials Group (CCTG) PR21 trial (NCT04663997), a Phase II study comparing docetaxel with lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). QoL worsened over time with docetaxel but remained largely stable with lutetium-PSMA, and patients reported more perceived side effects with docetaxel. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.